Gilead Sciences, Inc. vs Teva Pharmaceutical Industries Limited: A Gross Profit Performance Breakdown

Gilead vs. Teva: A Decade of Gross Profit Insights

__timestampGilead Sciences, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142110200000011056000000
Thursday, January 1, 20152863300000011356000000
Friday, January 1, 20162612900000011859000000
Sunday, January 1, 20172173600000010825000000
Monday, January 1, 2018172740000008296000000
Tuesday, January 1, 2019177740000007536000000
Wednesday, January 1, 2020201170000007725000000
Friday, January 1, 2021207040000007594000000
Saturday, January 1, 2022216240000006973000000
Sunday, January 1, 2023206180000007646000000
Monday, January 1, 2024782000008064000000
Loading chart...

Unleashing insights

A Decade of Gross Profit: Gilead Sciences vs. Teva Pharmaceuticals

In the ever-evolving pharmaceutical industry, Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited have been key players. From 2014 to 2023, Gilead consistently outperformed Teva in gross profit, peaking in 2015 with a 36% higher profit than its 2014 figures. However, the subsequent years saw a decline, with a notable 40% drop by 2018. Meanwhile, Teva's gross profit remained relatively stable, with a slight dip of 37% from its 2016 peak to 2022. Despite these fluctuations, Gilead maintained an average gross profit nearly double that of Teva over the decade. This performance highlights Gilead's robust market position, even amidst industry challenges. As the pharmaceutical landscape continues to shift, these insights provide a glimpse into the financial health and strategic positioning of these two giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025